Evidence map›Paper›PMID 38564029›Full record

ReviewClinical and experimental medicine2024

Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.

Yizi Gong, Chanjuan Shen, Ting Meng, Wei Lin, Xueling Hu, Rong Tang, Qi Xiong, Joshua D Ooi, Peter J Eggenhuizen, Jinbiao Chen and 7 more

Abstract readReview
In one paragraph

Review in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yizi GongDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Chanjuan ShenDepartment of Hematology, The Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, China.
Ting MengDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Wei LinDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Xueling HuDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Rong TangDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Qi XiongDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Joshua D OoiDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Peter J EggenhuizenCentre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences, Monash University, Clayton, VIC, Australia.
Jinbiao ChenDepartment of Medical Records and Information, Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Ya-Ou ZhouDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Hui LuoDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Jia XuDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Ning LiuDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Ping XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China.
Xiangcheng XiaoDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China. xiaoxc@csu.edu.cn.
Yong ZhongDepartment of Nephrology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan Province, China. zhongyong121@163.com.

Funding

the Project of Health Commission of Hunan Province A202303050036"YiluqihangShenmingyuanyang" medical development And Scientific Research Fund project on Kidney Diseases "YiluqihangShenmingyuanyang" medical development And Scientific Research Fund project on Kidney Diseases
6 · The paper itself

Abstract

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patients with dual positivity for proteinase 3-ANCA (PR3-ANCA) and myeloperoxidase-ANCA (MPO-ANCA) are uncommon. We aimed to investigate these idiopathic double-positive AAV patients' clinical features, histological characteristics, and prognosis. We reviewed all the electronic medical records of patients diagnosed with AAV to obtain clinical data and renal histological information from January 2010 to December 2020 in a large center in China. Patients were assigned to the MPO-AAV group or PR3-AAV group or idiopathic double-positive AAV group by ANCA specificity. We explored features of idiopathic double-positive AAV. Of the 340 patients who fulfilled the study inclusion criteria, 159 (46.76%) were female, with a mean age of 58.41 years at the time of AAV diagnosis. Similar to MPO-AAV, idiopathic double-positive AAV patients were older and had more severe anemia, lower Birmingham Vasculitis Activity Score (BVAS) and C-reactive protein (CRP) levels, less ear, nose, and throat (ENT) involvement, higher initial serum creatinine and a lower estimated glomerular filtration rate (eGFR) when compared with PR3-AAV (P < 0.05). The proportion of normal glomeruli of idiopathic double-positive AAV was the lowest among the three groups (P < 0.05). The idiopathic double-positive AAV patients had the worst remission rate (58.8%) among the three groups (P < 0.05). The relapse rate of double-positive AAV (40.0%) was comparable with PR3-AAV (44.8%) (P > 0.05). Although there was a trend toward a higher relapse rate of idiopathic double-positive AAV (40.0%) compared with MPO-AAV (23.5%), this did not reach statistical significance (P > 0.05). The proportion of patients who progressed to ESRD was 47.1% and 44.4% in the idiopathic double-positive AAV group and MPO-AAV group respectively, without statistical significance. Long-term patient survival also varied among the three groups (P < 0.05). Idiopathic double-positive AAV is a rare clinical entity with hybrid features of MPO-AAV and PR3-AAV. MPO-AAV is the "dominant" phenotype in idiopathic double-positive AAV.

Indexed as

Antibodies, Antineutrophil CytoplasmicAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisFemaleHumansMaleMiddle AgedMyeloblastinPeroxidasePrognosisRecurrenceAntibodies, Antineutrophil CytoplasmicMyeloblastinPeroxidaseANCA-associated vasculitisDouble-positive vasculitisMyeloperoxidasePrognosisProteinase 3

Identifiers

PMID38564029
PMCPMC10987344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.